Step 2 is consulting early with customers to define their drug delivery needs and determine the optimally suited container and device solution.
Step 1 is forming a cross-functional project team mirroring a customer’s own, facilitating interaction at every level and allowing BD to be an extension of each customer’s organization. BD understands that meeting customers’ complex and evolving needs requires extensive consultation throughout the entire process from development through commercialization, and has built an organization and capabilities that deliver support at every step. BD Neopak™ glass PFS became available in June 2013 and is expected to reset the standard for quality and innovation in delivery of today’s novel drug therapies.īD’s philosophy is the same today as it always has been: to be a total solutions provider for customers across all aspects of delivery for injectable drug products. More recently, BD introduced the BD HyFlow™ needle, a novel 27-gauge, special thin-walled (STW) needle that allows comfortable injection of highly viscous biopharmaceuticals. From this, BD developed a low-tungsten forming process in 2006 to achieve the lowest possible tungsten levels and avoid interactions with the drug product. In 2005, BD launched the Sensitive Drug InitiativeSM (SDI), partnering with drug manufacturers to understand interactions between drug products and their primary containers. Today, BD offers a wide range of products that include glass PFS, plastic syringes, self-injection devices, safety and shielding systems, and needle technology.
Since the first BD Hypak™ glass prefillable syringe (PFS) was introduced in 1954, BD has continued to innovate, developing ever more efficient manufacturing processes, novel technologies, and improved patient experiences.
For more than 50 years, BD (Becton, Dickinson and Company) has been a leader in providing the most advanced drug delivery solutions.
0 kommentar(er)
